Educational text messages to improve heart health in people with HIV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of sending educational text messages to individuals living with HIV to help reduce their cardiovascular risk. The intervention targets people aged 40 and older who are HIV positive and aims to provide them with vital information about managing their heart health. Participants will receive digital educational messaging designed to promote healthier lifestyle choices and awareness of cardiovascular health. The study is conducted by the University of California, San Francisco, in collaboration with the National Heart, Lung, and Blood Institute.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HIV positive
* At least 40 years of age
* English-speaking

Exclusion Criteria:

* Existing clinical atherosclerotic cardiovascular disease (ASCVD)
* Pregnant
* Unwilling/unable to provide informed consent
* Does not own a smartphone

Where it's running

• Zuckerberg San Francisco General Hospital
  San Francisco, California, United States Recruiting
• University of California San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Megan McLaughlin, MD, MPH — University of California, San Francisco
• Study coordinator: Megan McLaughlin, MD, MPH
• Email: teachhiv@ucsf.edu
• Phone: 628-206-8037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• See if Lepodisiran lowers coronary plaque in people with high Lp(a) and heart disease risk

  This study tests whether lepodisiran can reduce heart-artery plaque in adults with high Lp(a) compared to placebo.

  Recruiting at 53 sites Phase 3 Eli Lilly and Company · La Jolla, California and 56 other locations · NCT07613294

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

• Investigating heart-related side effects of cancer immunotherapy

  This study is testing whether cancer immunotherapy treatments can cause heart problems in patients with certain types of cancer.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT06519292

• Cardiovascular risk assessment for patients with lipid disorders in emergency care

  This study is testing a new way to help emergency room patients with high cholesterol lower their heart disease risk by providing better care compared to the usual treatment.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT06488105

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.